These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19118064)

  • 1. Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between Japanese and Western patients.
    Latz JE; Schneck KL; Nakagawa K; Miller MA; Takimoto CH
    Clin Cancer Res; 2009 Jan; 15(1):346-54. PubMed ID: 19118064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
    Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
    Latz JE; Rusthoven JJ; Karlsson MO; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):427-35. PubMed ID: 16322992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
    Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
    J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
    Takimoto CH; Hammond-Thelin LA; Latz JE; Forero L; Beeram M; Forouzesh B; de Bono J; Tolcher AW; Patnaik A; Monroe P; Wood L; Schneck KB; Clark R; Rowinsky EK
    Clin Cancer Res; 2007 May; 13(9):2675-83. PubMed ID: 17473199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed].
    Tsuda Y; Kitamura A; Nishimura N; Yagi N; Takayama S; Okafuji K; Tomishima Y; Jinta T; Koyama K; Ohde S; Gotoh K; Chohnabayashi N
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):471-5. PubMed ID: 25963695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.
    Nakagawa K; Kudoh S; Matsui K; Negoro S; Yamamoto N; Latz JE; Adachi S; Fukuoka M
    Br J Cancer; 2006 Sep; 95(6):677-82. PubMed ID: 16940981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.
    Li KM; Rivory LP; Clarke SJ
    Br J Cancer; 2007 Oct; 97(8):1071-6. PubMed ID: 17912246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer.
    Takagi Y; Hosomi Y; Sunami K; Nakahara Y; Okuma Y; Yomota M; Shimokawa T; Nagamata M; Iguchi M; Okamoto H; Okamura T; Shibuya M
    Oncologist; 2014 Nov; 19(11):1194-9. PubMed ID: 25260366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.
    Kim YS; Sun JM; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2013 Aug; 81(2):231-5. PubMed ID: 23683535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study.
    Llombart-Cussac A; Theodoulou M; Rowland K; Clark RS; Nakamura T; Carrasco E; Cruciani G
    Clin Breast Cancer; 2006 Dec; 7(5):380-5. PubMed ID: 17239262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer.
    Bajetta E; Celio L; Buzzoni R; Ferrari L; Marchianò A; Martinetti A; Longarini R; Becerra C; Ilardi C; John W
    Ann Oncol; 2003 Oct; 14(10):1543-8. PubMed ID: 14504056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
    Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
    Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trials of pemetrexed.
    Fossella FV; Gatzemeier U
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):8-16. PubMed ID: 12023787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
    Galsky MD; Mironov S; Iasonos A; Scattergood J; Boyle MG; Bajorin DF
    Invest New Drugs; 2007 Jun; 25(3):265-70. PubMed ID: 17146733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed safety and dosing strategy.
    Niyikiza C; Hanauske AR; Rusthoven JJ; Calvert AH; Allen R; Paoletti P; Bunn PA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):24-9. PubMed ID: 12571807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.